Martha Abrahamsen

Martha Abrahamsen

Auto-generated profile, based on publicly available information

Martha Abrahamsen

University of South Florida Morsani College of Medicine, Tampa (M. Bikowitz

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Papillomavirus Research
Verified
Journal Article
Open access
AGAnna R. Giuliano
Anna R. Giuliano
RVRaphael P Viscidi
Raphael P Viscidi
BTB. Nelson Torres
B. Nelson Torres
DIDonna J. Ingles
Donna J. Ingles
SSStaci Sudenga
Staci Sudenga
ELEduardo Lazcano-Ponce
Eduardo Lazcano-Ponce
Protection from naturally acquired human papillomavirus (HPV) antibodies may influence HPV infection across the lifespan. This study describes seroconversion rates following genital, anal, and oral HPV 6/11/16/18 infections in men and examines differences by HPV type and anatomic site. Men with HPV 6/11/16/18 infections who were seronegative for those genotypes at the time of DNA detection were selected from the HPV Infection in Men (HIM) Study. Sera specimens collected ≤36 months after detection were analyzed for HPV 6/11/16/18 antibodies using a virus-like particle-based ELISA. Time to seroconversion was separately assessed for each anatomic site, stratified by HPV type. Seroconversion to ≥1 HPV type (6/11/16/18) in this sub-cohort (N=384) varied by anatomic site, with 6.3%, 18.9%, and 0.0% seroconverting following anal, genital, and oral HPV infection, respectively. Regardless of anatomic site, seroconversion was highest for HPV 6 (19.3%). Overall, seroconversion was highest following anal HPV 6 infection (69.2%). HPV persistence was the only factor found to influence seroconversion. Low seroconversion rates following HPV infection leave men susceptible to recurrent infections that can progress to HPV-related cancers. This emphasizes the need for HPV vaccination in men to ensure immune protection against new HPV infections and subsequent disease.

11 November 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
DBDeepti Bettampadi
Deepti Bettampadi
BSBradley A Sirak
Bradley A Sirak
MAMartha E Abrahamsen
Martha E Abrahamsen
RRRichard R Reich
Richard R Reich
LVLuisa Villa
Luisa Villa
AGAnna R Giuliano
Anna R Giuliano
Human papillomavirus (HPV)–attributable oropharyngeal cancer (HPV-OPC) incidence is increasing in many high-income countries among men. Factors associated with oral HPV persistence, the precursor of HPV-OPC, are unknown. Data from the HPV Infection in Men (HIM) Study, which followed participants >7 years, were utilized to examine rates of persistence and associated factors. Oral gargle samples from 3095 HIM study participants were HPV genotyped using the SPF10 PCR-DEIA-LiPA25 assay (DDL Diagnostic Laboratory). Oral HPV persistence for individual and grouped high-risk HPV types among 184 men positive for any high-risk HPV at their oral baseline visit was assessed at 6-month intervals. Factors associated with grouped high-risk HPV/HPV16 persistence were examined using logistic regression. Kaplan-Meier curves were constructed to examine median time to HPV clearance overall, and by selected risk factors. Among the 7 HPV vaccine types, HPV33 had the longest median duration (7.6 months) followed by HPV16 and HPV45 (6.4 months). 10–30% of oral high-risk HPV infections persisted ≥24 months. Six months’ persistence of oral high-risk HPV infections was positively associated with age and gingivitis and negatively with lifetime number of sexual partners, while 12 months’ persistence was only inversely associated with lifetime number of sexual partners. Oral HPV16 persistence was positively associated with baseline HPV16 L1 antibody status. Eighteen percent of HPV16 infections persisted beyond 24 months, potentially conferring higher risk of HPV-OPC among these men. Older age appears to be an important factor associated with oral high-risk HPV persistence. More studies among healthy men are required to understand the progression of oral HPV infection to HPV-OPC.

1 November 2009 in Sexually Transmitted Diseases
Verified
Journal Article
Closed access
EDEileen F. Dunne
Eileen F. Dunne
CNCarrie M. Nielson
Carrie M. Nielson
MHMichael E. Hagensee
Michael E. Hagensee
MPMary R. Papenfuss
Mary R. Papenfuss
RHRobin B. Harris
Robin B. Harris
AGAnna R. Giuliano
Anna R. Giuliano
A vaccine to prevent human papillomavirus (HPV) 6, HPV 11, HPV 16, or HPV 18 and associated diseases is licensed for females, and it may be licensed for men in the future. There are limited data on HPV 6/11, 16, and/or 18 seroprevalence in men. A total of 490 men aged 18 to 40 years were enrolled in a study of HPV in men in Tucson, AZ, and Tampa, FL. Enrolled men completed a self-administered questionnaire, and HPV serology was performed using HPV 6/11, 16, and 18 VLP assays. Overall, seroprevalence to HPV 16 was 12.1%, HPV 6/11 was 9.7%, and to HPV 18 was 5.4%. Seroprevalence to HPV 6/11, 16, and/or 18 was 21% and was highest among 35 to 40 year olds (48%); prevalence in this age group was significantly higher compared to the 18 to 24 year olds (adjusted odds ratio (aOR) 6.8, 95% confidence interval (CI) 3.7, 12.8). Independent predictors of seropositivity to HPV 6/11, 16, and/or 18 were older age, greater number of female sex partners in the past 3 months, and current smoking. HPV vaccine-type seroprevalence was highest in 35 to 40 year old men. These data on the epidemiology of HPV seroprevalence in men are useful for discussions regarding recommendations for HPV vaccine if licensed for use in men.

1 September 2002
Verified
Journal Article
Closed access
RSRebecca L Sedjo
Rebecca L Sedjo
DRDenise J Roe
Denise J Roe
MAMartha Abrahamsen
Martha Abrahamsen
RHRobin B Harris
Robin B Harris
NCNeal Craft
Neal Craft
AGAnna R Giuliano
Anna R Giuliano

4 December 2003 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
AGAnna R. Giuliano
Anna R. Giuliano
MPMary Papenfuss
Mary Papenfuss
EGElena Mendez Brown de Galaz
Elena Mendez Brown de Galaz
JFJanine Feng
Janine Feng
MAMartha Abrahamsen
Martha Abrahamsen
KHKenneth Hatch
Kenneth Hatch
It is now well established that cervical cancer is caused by oncogenic human papillomavirus (HPV) infections that commonly infect women worldwide. What remains to be understood are the factors that contribute to cervical cancer in the presence of HPV infection. We conducted a case-control analysis of women recruited at the US-Mexico border to simultaneously evaluate factors associated with 3 cytologic outcomes: atypical squamous cells of undetermined significance or atypical glandular cells of undetermined significance (ASCUS/AGUS), low grade squamous intraepithelial lesions (LSIL) and high grade squamous intraepithelial lesions (HSIL). A cross-sectional binational study of 2,059 women ages 15–79 years was conducted between 1997 and 1998. A significant difference in the distribution of cytologic categories by country was observed (3.0% vs. 0.7% HSIL among Mexican vs. US women, respectively). The only factors independently associated with all 3 cytologic outcomes were HPV infection and viral load. A linear increase in risk with increasing viral load was observed for each of the 3 outcome variables, with the strength of this association increasing with cytology abnormality. In addition to HPV infection, parity and Mexico as a country of residence appear to be associated with LSIL and HSIL, respectively. Factors associated with cytologic outcomes in analyses limited to women with HPV infection were similar to results obtained in models where HPV infection was included as a covariate. Future work is needed to evaluate the predictive value of HPV viral load utilizing more specific and quantitative measures.

1 April 2002
Verified
Journal Article
Closed access
RSRebecca L Sedjo
Rebecca L Sedjo
PIPaula Inserra
Paula Inserra
MAMartha Abrahamsen
Martha Abrahamsen
RHRobin B Harris
Robin B Harris
DRDenise J Roe
Denise J Roe
AGAnna R Giuliano
Anna R Giuliano